EVAX Share Price Performance
US$3.78
2.27 (150.33%)
80.9% undervalued intrinsic discount
US$19.75
Fair Value
Price US$3.78
AnalystHighTarget US$19.75
Talos US$15.85
AnalystLowTarget US$9.00
Fair ValueUS$19.75
Share Pricen/a
Evaxion A/S Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 20 Fair Values set on narratives written by author
EVAX Community Narratives
AN
Fair Value US$19.75 80.9% undervalued intrinsic discount
AI Immunology Partnerships And Pipeline Progress Will Drive Long Term Value
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
TA
Fair Value US$15.85 76.2% undervalued intrinsic discount
The "AI-Immunology" Asymmetric Opportunity – Validated by Merck (MSD)
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$9 58.0% undervalued intrinsic discount
AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
The "AI-Immunology" Asymmetric Opportunity – Validated by Merck (MSD)
Evaxion Biotech is a micro-cap TechBio company punching significantly above its weight class. While the market views it as a small preclinical player, its proprietary AI-Immunology™ platform has already secured a massive validation: a partnership with Merck (MSD).Read more
97
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience
Catalysts About Evaxion Evaxion is a biotech company that applies its AI-Immunology platform to discover and design vaccines and immunotherapies in oncology, infectious disease and potentially autoimmune conditions. What are the underlying business or industry changes driving this perspective?Read more
4
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$9
58.0% undervalued intrinsic discount
Fair Value
Profit Margin
36.25%
Future PE
6.31x
Price in 2029
US$11.14
AI Immunology Partnerships And Pipeline Progress Will Drive Long Term Value
Catalysts About Evaxion Evaxion is a biotech company that uses its AI-Immunology platform to design personalized and off the shelf vaccines for cancer and infectious diseases. What are the underlying business or industry changes driving this perspective?Read more
20
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$19.75
80.9% undervalued intrinsic discount
Fair Value
Profit Margin
33.88%
Future PE
9.8x
Price in 2029
US$23.99
AI-Driven Vaccine Partnerships And Dark Genome Targets Will Shape Long-Term Opportunity
Catalysts About Evaxion Evaxion develops AI driven immunology platforms to design personalized and off the shelf vaccines for cancer and infectious diseases. What are the underlying business or industry changes driving this perspective?Read more
12
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$14.19
73.4% undervalued intrinsic discount
Fair Value
Profit Margin
25.38%
Future PE
17.04x
Price in 2028
US$17.23
Trending Discussion
Recently Updated Narratives
TA
The "AI-Immunology" Asymmetric Opportunity – Validated by Merck (MSD)
Fair Value: US$15.85 76.2% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience
Fair Value: US$9 58.0% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AI Immunology Partnerships And Pipeline Progress Will Drive Long Term Value
Fair Value: US$19.75 80.9% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Evaxion A/S Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 07, 2026
- -0.92
- 100.00%
- -102.38%
- 32.5%
About EVAX
- Founded
- 2008
- Employees
- 46
- CEO
- WebsiteView website
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
